journal

We’re thrilled to announce that our first peer-reviewed study is now published in Frontiers in Psychiatry: Safety, effectiveness and tolerability of sublingual ketamine in depression and anxiety: A retrospective study of off-label, at-home use.

Frontiers in Psychiatry is one of the most-cited medical journals in mental health. The study was conducted with 664 of our patients, the second largest data set of any at-home sublingual ketamine treatment protocol.

The study analyzed the impact of our treatment protocol on patients with treatment-resistant depression and anxiety. It showed that after as few as three doses of ketamine therapy, nearly 50% of patients with moderate to severe depression saw a clinical response defined as a 50% reduction in their baseline PHQ-9 and GAD-7 scores (the standardized clinical measures of depression and anxiety, respectively). The clinical response rate improved to over 60% in patients who completed six doses.

The study was led by Nue Life’s Chief Medical Officer, Kazi Hassan, MD. Additional authors are William M. Struthers, PhD; Patrick Davis, MD, PhD; and Aditya Sankarabhotla, Nue Life’s VP of AI & Technology.

Read the full study here.

‍